B. Sjoquist et al., Pharmacokinetics of latanoprost in the cynomolgus monkey - 1st Communication: Single intravenous, oral or topical administration on the eye, ARZNEI-FOR, 49(3), 1999, pp. 225-233
Latanoprost (13,14-dihydro-15(R)-17-phenyl-18,19,20-trinor-PGF(2a)- isoprop
yl eater, CAS 130209-82-4 PhXA41, Xalatan(R)) is a prodrug used for reducti
on of the intraocular pressure in the treatment of glaucoma. The pahrmacoki
netics of this drug was studied in the cynomolgus monkey after intravenous,
oral and topical administration of 9 beta-[H-3] labelled latanoprost. The
plasma profile of radioactivity from HPLC separation of samples obtained af
ter intravenous as well as topical administration on the eyes showed a rapi
d and complete hydrolysis of the ester. The pharmacologically active acid o
f latanoprost showed a maximum concentration 5 min post topical administrat
ion and an elimination half-life of about 10 min. Tertiary butyldimethylsil
yl derivatives were prepared of the radioactive fractions collected from th
e HPLC column. The derivatives were analysed by gas chromatography-mass spe
ctrometry (GC-MS). After oral administration no latanoprost and very little
of its acid was present in plasma, indicating a first-pass metabolism resu
lting in more polar compounds.
Based on the retention times on the HPLC and GC and on a mass spectrum simi
lar to the acid of latanoprost but 28 daltons lower, the main metabolite in
urine and faeces was identified as the 1,2-dinor acid of latanoprost. In a
similar way a more polar fraction from urine was identified as the 1,2,3,4
-tetranor metabolite of the acid of latanoprost.
The tissue distribution after i.v. and topical administration was similar w
ith organs of metabolism (liver) and elimination (kidney) containing the hi
ghest concentrations. After topical application much of the dose was found
in the anterior ocular tissues but not in the posterior parts of the eye.
In conclusion, latanoprost is a prodrug which in vivo rapidly is hydrolysed
to the corresponding free acid. The acid of latanoprost has a short half-l
ife in plasma and is extensively metabolised mainly through beta-oxidation
before it is excreted into the urine and faeces.